Dexcom opened higher at $81.52, compared with its previous close of $79.93. In the last trading session, the stock traded between $79.79 and $85.25. It showed an upward intraday trend.
An investment of $100 made 5 years ago in Dexcom is now worth
$ 53.89
resulting in a loss of
$ 46.11 (46.11%)
Note: Past profits do not guarantee future returns.
Rating from 19 Analysts
Today's Change
+$4.04 (+5.05%)
Day High
$85.25
Day Low
$79.79
Day Open
$81.52
Prev Close
$79.93
Volume
42,49,073
1W Return
7.21%
1M Return
-3.07%
3M Return
11.72%
6M Return
45.87%
1Y Return
23.15%
Market Cap ($ Mn)
31,685
PE Ratio
36.04
PB Ratio
13.08
PEG Ratio
2.96
ROE
33.68%
ROCE
25.30%
EPS (TTM)
$0.66
1 Week
7.21%
1 Month
-3.07%
3 Months
11.72%
6 Months
45.87%
9 Months
13.47%
Dexcom G7 cuts A1C by 1.6% in Type 2 diabetes trial published in NEJM
Dexcom G7 users saw 1.6% A1C reduction vs routine care. Study supports CGM for Type 2 diabetes patients not on insulin. Benefits observed in patients over 65 and GLP-1 medication users. 97% participant retention rate maintained through 26-week study.
15 days agoDexcom releases 2026 report on Type 2 diabetes care gaps
Dexcom surveyed 800 healthcare professionals and 2,500 patients across eight countries. 55% of Type 2 diabetes patients report limited knowledge of CGM technology. 90% of US healthcare professionals cite coverage as a barrier to CGM adoption. 58% of GLP-1 users pair medication with CGM, versus 27% of non-insulin users. Dexcom partners with Team Novo Nordisk to support Type 1 diabetes awareness.
1mo agoDexcom promotes CFO Jereme Sylvain to Chief Operating Officer
Jereme Sylvain promoted to COO while retaining CFO duties at Dexcom. New role includes oversight of global operations and quality teams. Sylvain has served as CFO since 2021 after joining in 2018. CEO Jake Leach cites operational discipline as key driver for promotion.
1mo agoDexcom appoints former Stryker CFO Glenn Boehnlein to board
Dexcom appoints Glenn Boehnlein to its Board of Directors effective September 10, 2026. Boehnlein previously served as CFO of Stryker Corporation from 2016 to 2025. CEO Jake Leach cited Boehnlein’s expertise in organic revenue growth and cash flow. Boehnlein currently serves on boards of Inogen Inc. and Agilent Technologies Inc.
1mo agoHalper Sadeh investigates DexCom insiders for fiduciary duty breach
Halper Sadeh LLC is investigating whether officers and directors of DexCom, Inc. breached fiduciary duties to shareholders. The investigation was announced on September 7, 2026. Long-term DexCom shareholders may be eligible for corporate governance reforms, return of funds, or a court-approved financial incentive award. The firm offers to handle matters on a contingent fee basis, with no out-of-pocket legal fees for shareholders. Shareholders are urged to act promptly as there may be limited time to enforce their rights.
1mo agoDexCom raises FY26 sales guidance to $5.18B-$5.25B on strong Q2 growth
DexCom delivered strong Q2 2026 results with $1.308 billion in revenue and expanded margins, leading to a raise in full-year sales guidance to $5.180B-$5.250B. International revenue grew 19%, and GAAP operating income reached $318.3 million. Strategic updates include positive CONNECT trial results and a new long-term outlook through 2030.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $104.57 | +1.88% | $1,80,946.15M | 36.28 | |
| $448.76 | +1.03% | $1,55,559.96M | 42.73 | |
| $97.11 | +2.46% | $1,24,220.20M | 24.46 | |
| $311.75 | +2.55% | $1,19,578.88M | 34.27 | |
| $42.69 | +0.61% | $61,867.63M | 18.96 | |
| $94.44 | +2.90% | $54,435.22M | 53.70 | |
| $198.34 | +1.63% | $54,025.24M | 44.07 | |
| $252.83 | +1.06% | $35,557.76M | 23.04 | |
| $76.42 | +0.79% | $34,552.39M | 16.49 | |
| $71.13 | +1.86% | $34,384.24M | 54.55 | |
| $416.67 | +3.23% | $29,323.57M | 43.21 | |
| $32.00 | -1.14% | $28,075.23M | 89.05 |
An investment of $100 made 5 years ago in Dexcom is now worth
$ 53.89
resulting in a loss of
$ 46.11 (46.11%)
Note: Past profits do not guarantee future returns.
